Sugi Predict

Sugi Predict / Compounds / SCHEMBL8716211

SCHEMBL8716211

SCHEMBL8716211

O=C(SSC(=O)c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 3/20 0.59
▸ CES1 P23141 3/20 0.59
▸ TSHR P16473 2/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ CA1 P00915 2/20 0.54
▸ CA2 P00918 2/20 0.54
▸ GSK3B P49841 2/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ SRD5A2 P31213 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ CYP3A4 P08684 1/20 0.44
▸ ATM Q13315 1/20 0.44
▸ PTGS2 P35354 1/20 0.43
▸ ERCC5 P28715 1/20 0.43
▸ FEN1 P39748 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13571696 0.84 CES2 (0.59) CES2CES1TSHRALOX15CA1
SCHEMBL9727180 0.80 CES2 (0.54) CES2CES1TSHRALOX15CA1
SCHEMBL9727178 0.80 CES2 (0.54) CES2CES1TSHRALOX15CA1
SCHEMBL28692407 0.80 CES2 (0.48) CES2CES1TSHRALOX15CA1
SCHEMBL27870723 0.78 CES2 (0.52) CES2CES1TSHRALOX15CA1
SCHEMBL11424462 0.77 GSK3B (0.54) CES2CES1TSHRALOX15CA1
SCHEMBL8712153 0.76 MAPT (0.57) CES2ALOX15CA1CA2MAPK1
SCHEMBL8715068 0.76 TSHR (0.67) CES2CES1TSHRALOX15CA1
SCHEMBL6583812 0.75 KDM4E (0.55) CES2CES1TSHRALOX15CA1
SCHEMBL9727111 0.75 CES2 (0.48) CES2CES1TSHRALOX15CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264174-B2 Process for preparing imetelstat GERON CORPORATION (US) 2025-04-01 — — US claimed
US-20240262854-A1 Process for Preparing Imetelstat BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) 2024-08-08 — — US claimed
CN-110891961-B Improved process for the preparation of imaelstat 美国杰龙生物医药公司 2023-06-30 — — CN claimed
US-11332489-B2 Process for preparing imetelstat GERON CORPORATION (US) 2022-05-17 — — US claimed
EP-3652187-B1 IMPROVED PROCESS FOR PREPARING IMETELSTAT GERON CORP (US) 2021-09-15 — — EP claimed
US-20200369702-A1 Improved Process for Preparing Imetelstat BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) 2020-11-26 — — US claimed
EP-3652187-A1 IMPROVED PROCESS FOR PREPARING IMETELSTAT GERON CORPORATION (US) 2020-05-20 — — EP claimed
CN-110891961-A Improved process for the preparation of isomestat (imetelstat) 美国杰龙生物医药公司 2020-03-17 — — CN claimed
WO-2019011829-A1 IMPROVED PROCESS FOR PREPARING IMETELSTAT JANSSEN PHARMACEUTICA NV (BE) 2019-01-17 — — WO claimed
US-12264174-B2 Process for preparing imetelstat GERON CORPORATION (US) 2025-04-01 — — US disclosed
US-20240262854-A1 Process for Preparing Imetelstat BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) 2024-08-08 — — US disclosed
US-20240199672-A1 Process for Preparing Imetelstat BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) 2024-06-20 — — US disclosed
CN-110891961-B Improved process for the preparation of imaelstat 美国杰龙生物医药公司 2023-06-30 — — CN disclosed
US-20230070069-A1 Process for Preparing Imetelstat GERON CORPORATION 2023-03-09 — — US disclosed
CN-110891961-A Improved process for the preparation of isomestat (imetelstat) 美国杰龙生物医药公司 2020-03-17 — — CN disclosed
WO-2019011829-A1 IMPROVED PROCESS FOR PREPARING IMETELSTAT JANSSEN PHARMACEUTICA NV (BE) 2019-01-17 — — WO disclosed
US-5847061-A Process for producing polymers having terminal functional group which may be protected KURARAY CO., LTD. (JP) 1998-12-08 — — US disclosed
EP-0704460-B1 PROCESS FOR PRODUCING POLYMER TERMINATED WITH OPTIONALLY PROTECTED FUNCTIONAL GROUP KURARAY CO (JP) 1998-11-04 — — EP disclosed
EP-0704460-A1 PROCESS FOR PRODUCING POLYMER TERMINATED WITH OPTIONALLY PROTECTED FUNCTIONAL GROUP KURARAY CO., LTD. (JP) 1996-04-03 — — EP disclosed
US-4245033-A AN ORGANIC SILVER SALT, A HALIDE AND A SULFUR COMPOUND EXPOSED TO FORM A SILVER IMAGE OF HIGH CONTRAST AND STABILITY CANON KABUSHIKI KAISHA (JP) 1981-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230070069-A1 Process for Preparing Imetelstat TERT, RNGTT, TRMT1L CES2 3750/4885CES1 2380/4885TSHR 1886/4885
US-11332489-B2 Process for preparing imetelstat RNGTT, TERT, TRMT1L CES2 3546/4885CES1 2345/4885TSHR 2083/4885
US-20200369702-A1 Improved Process for Preparing Imetelstat RNGTT, TERT, TRMT1L CES2 3585/4885CES1 2398/4885TSHR 2231/4885
US-20240262854-A1 Process for Preparing Imetelstat TERT, RNGTT, TRMT1L CES2 3750/4885CES1 2380/4885TSHR 1886/4885
US-12264174-B2 Process for preparing imetelstat TERT, RNGTT, TRMT1L CES2 3750/4885CES1 2380/4885TSHR 1886/4885
US-20240199672-A1 Process for Preparing Imetelstat TERT, RNGTT, TRMT1L CES2 3750/4885CES1 2380/4885TSHR 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.